Delcath Systems Inc (DCTH): Earnings growth forecast for next year
The growth of Delcath Systems, Inc. (DCTH) is independent of macroeconomics, relying solely on the implementation of perfusion systems. Absolute pricing power and inelastic demand for HEPZATO ensure financial stability. The synergy of these factors and the work of top experts is evident in the consensus net profit growth estimates on the basic chart of the GURU.Markets service, where 182.60 expresses the latest metric level.
Analytical breakdowns for Delcath Systems, Inc.
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- debt obligations and liquidity statistics:
Total Debt to Capital Delcath Systems, Inc.|DCTH - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Delcath Systems|DCTH - Company Aggregate Debts|Debt to Book Value Delcath Systems|DCTH - Amount of Long-Term Liabilities|Company Short-Term Debts Delcath Systems|Quick Liquidity Indicator delcath.com
- earnings and valuation multiples information:
DCTH - Final Profit|Expected Profit Delcath Systems, Inc.|DCTH - Business Payback Period|Projected Price to Earnings Delcath Systems, Inc.|DCTH - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Delcath Systems|DCTH - Operating income before deduction of amortization|Net earnings per share for the last 12 months Delcath Systems|DCTH - Earnings per share for the last four quarters|Quarterly EPS earnings growth delcath.com|DCTH - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Delcath Systems, Inc.
Basic company analysis:Delcath
This indicator reflects the trend of analyst expectations regarding earnings per share changes for the coming year, capturing daily adjustments to fundamental valuations. Investors determine the true strength of an issuer through consolidation periods or reversals in the promising trajectory of EPS growth estimates. A positive trend signals an upward revision of the asset's value. For Delcath Systems, Inc. (DCTH), this is directly linked to the implementation efficiency of the Hepzato Kit and the expansion rate of the specialized clinic network.
Direct competitors
ONC (BeiGene Corp) - Earnings growth forecast for next year|Expected net earnings per share growth next year Halozyme Corp HALO|Earnings growth forecast for next year RVMD|ascentage.com - Projected earnings per share growth rate for next year|Earnings growth forecast for next year CGON (CG Oncology)|UroGen Pharma Ltd (URGN) - Expected net earnings per share growth next year|BCAX - Net earnings per share growth forecast for next year|PSNL: Net earnings per share growth forecast for next year|ERAS: Earnings growth forecast for next year|Expected earnings per share growth for next year ymabs.com|AURA (Aura Biosciences) - Earnings growth forecast for next year|Earnings growth forecast for next year Candel|Expected earnings per share growth for next year ARAY (Accuray Inc.)|Projected earnings per share increase next year SLS|Earnings growth forecast for next year ACTU (Actuate Therapeutics, Inc.)|Expected earnings per share trend next year CTOR|HURA: Expected earnings per share growth for next year|Expected earnings per share trend next year TARA (Protara Therapeutics Inc)|Fate Therapeutics Corp (FATE) - Net earnings per share growth forecast for next year|WHWK - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year TCRX|Expected net earnings per share growth next year Champions Oncology Corp CSBR|Net earnings per share growth forecast for next year XBiotech Inc. (XBIT)|Consensus forecast of earnings per share growth for next year cel-sci.com|OS Therapies Inc - Expected earnings per share growth for next year|Projected earnings per share increase next year RADX (radiopharmtheranostics.com)|Artiva - Earnings growth forecast for next year|Expected net earnings per share growth next year Adlai Nortye Ltd.|Veru (VERU) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year Tempest Therapeutics Inc|Net earnings per share growth forecast for next year Xilio Therapeutics Inc|Enochian BioSciences (RENB) - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year MURA (Mural Oncology plc)|KAPA (kairospharma.com) - Expected earnings per share trend next year|Earnings growth forecast for next year OKUR (OnKure Therapeutics)|Consensus forecast of earnings per share growth for next year CytoMed Therapeutics Ltd (GDTC)|CRIS - Net earnings per share growth forecast for next year|APLM (Apollomics, Inc.) - Projected earnings per share growth rate for next year|THAR: Earnings growth forecast for next year|Expected earnings per share growth for next year Advanced Biomed|Expected earnings per share growth for next year GNPX|Calidi Bio (CLDI) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year SBFM|xeneticbio.com - Projected earnings per share growth rate for next year|Earnings growth forecast for next year SLRX (Salarius Pharmaceuticals)|PPBT - Expected earnings per share growth for next year|AONC: Expected earnings per share growth for next year|BeiGene Ltd. - Projected earnings per share increase next year|CKPT: Earnings growth forecast for next year|elevationoncology.com - Expected earnings per share trend next year|ICAD (iCAD Inc.) - Earnings growth forecast for next year|Expected earnings per share growth for next year Ikena (IKNA)|Earnings growth forecast for next year NTBL|Earnings growth forecast for next year viracta.com (VIRX)|Net earnings per share growth forecast for next year MorphoSys Corp MOR|NAYA: Projected earnings per share growth rate for next year|Ascentage Pharma Group - Earnings growth forecast for next year
